Forge Biologics Emphasizes Gene Therapy Focus and Rare Disease Mission

According to a recent LinkedIn post from Forge Biologics, the company is aligning itself with Rare Disease Day by emphasizing its focus on patients with rare genetic conditions. The post notes that more than 400 million people worldwide are affected by rare diseases and highlights the company’s workforce of more than 450 employees dedicated to gene therapy development.

The company’s LinkedIn post highlights a mission that extends beyond contract manufacturing toward broader collaboration with innovators to accelerate development and enable access to gene therapies. For investors, this positioning suggests a strategy centered on specialized, high-value services in the rare disease and gene therapy ecosystem, which could support premium pricing, deeper customer relationships, and potential long-term growth as the gene therapy market matures.